ASPI

ASP Isotopes Inc. (ASPI) - Form 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. ASP Isotopes Inc. is an advanced materials company developing isotope enrichment technologies (ASP and QE) for nuclear medicine, semiconductors, and nuclear energy. The company operates through three primary segments: Specialist Isotopes and Related Services, Nuclear Fuels, and Helium and LNG (following the acquisition of Renergen in January 2026). The company also reported the deconsolidation of its construction services subsidiary, Skyline, as discontinued operations in March 2026.

Key Financial Metrics (Six Months Ended June 30, 2026)

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $9.3 million from $2.3 million in the prior year period, driven by the acquisition of Renergen (Helium/LNG segment) and growth in radiopharmacy operations (PET/SPECT scanning).
• Operating Expenses: Operating expenses rose significantly to $62.2 million from $20.8 million, primarily due to increased personnel costs, professional fees related to acquisitions (Renergen, ECNP, Numed), and expanded R&D activities.
• Net Loss Improvement: While the company remains unprofitable, the net loss from continuing operations narrowed to $60.7 million from $83.6 million in the prior year. This improvement was largely due to a reduction in the non-cash fair value adjustment on convertible notes payable (from a $64.7 million loss in 2025 to a $4.0 million loss in 2026).
• Deconsolidation: The company deconsolidated Skyline in March 2026, resulting in a $19.3 million gain on deconsolidation and the classification of Skyline's results as discontinued operations.

Guidance, Outlook, and Risks

• Strategic Transactions: On June 25, 2026, the company entered into a Merger Agreement with ENDRA Life Sciences Inc. to combine Renergen with ENDRA. The transaction is subject to shareholder approval and other conditions, with a target closing in Q4 2026.
• Capital Requirements: Management expects current cash and investments ($254.9 million total) to fund operations for more than 12 months. However, significant capital is required for Phase 2 of the Virginia Gas Project (estimated at $1.16 billion) and isotope plant construction.
• Key Risks:
  • Regulatory Approvals: Success depends on obtaining licenses for uranium enrichment in South Africa and regulatory approvals for isotope products.
  • Debt Covenants: The company is currently in default on certain operating covenants for its DFC Credit Facility and IDC Loan due to delays in financial statement delivery and security registration. Waivers are being negotiated.
  • Legal Proceedings: A securities class action lawsuit is pending, with a settlement preliminarily approved by the court. Several derivative actions are also pending against directors.
  • Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, which management is actively remediating.

Investor Verification Checklist

• Debt Covenant Status: Verify the status of negotiations with the DFC and IDC regarding the waiver of default covenants and the potential for cross-defaults.
• Merger Conditions: Monitor the progress of the ENDRA Merger Agreement, specifically the receipt of the $50 million Noble Investment and shareholder approvals.
• Convertible Note Exchange: Review the impact of the July 2026 exchange of approximately $109.2 million of 2025 Convertible Notes for common stock on future dilution and debt obligations.
• Phase 2 Funding: Assess the feasibility of securing the estimated $1.16 billion required for Phase 2 of the Virginia Gas Project, given current market conditions and lender commitments.
• Legal Settlements: Track the final approval and terms of the securities class action settlement and the outcome of pending derivative lawsuits.